When combined with tofogliflozin, a highly selective sodium-glucose cotransporter-2 (SGLT2) inhibitor, pemafibrate treatment significantly prevents MASH development in rodents [117]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.